Home › Compare › GLYYY vs ABBV
GLYYY yields 1.43% · ABBV yields 3.06%● Live data
📍 GLYYY pulled ahead of the other in Year 6
Combined, GLYYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GLYYY + ABBV for your $10,000?
Glory Ltd. develops and manufactures cash handling machines and systems. It operates through Financial Market, Retail and Transportation Market, Amusement Market, and Overseas Market segments. The company provides teller cash recyclers, bank note counters, bank sorters, coin dispensers, coin sorters, coin counters, coin wrappers, and rolled coin dispensers, as well as self service solutions, bank note deposit solutions, and assisted service software solutions; cash recycling systems, front office-cash recyclers, banknote recyclers, payment station, and coin deposit solutions; remote customer displays; UW-F series; WR-90/500; and OEM cash dispensing systems, OEM cash deposit machines, and OEM cash recycling systems. The company also offers software solutions, such as business intelligence, device management, resource planning, retail cash management, serial number management, teller connectivity, and managed services. In addition, it offers professional, maintenance, and Ubiqular manage treasury managed services. Further, the company offers open teller systems, card systems, pachinko prize dispensing machines, and ticket vending machines, as well as self-service kiosks, mail ordering systems, and digital menu boards. It serves the CIT, financial, gaming, OEM, restaurant, amusement, and retail industries. The company was formerly known as Kokuei Machinery Manufacturing Co., Ltd. and changed its name to Glory Ltd. in 1971. The company was founded in 1918 and is headquartered in Himeji, Japan.
Full GLYYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.